科兴制药控股股东半月套现2.21亿元 2020年上市募11亿

Core Viewpoint - The major shareholder of Sinovac Biotech (科兴制药) has completed a share reduction plan, selling 5,989,200 shares, which is 3.00% of the total share capital, without triggering a mandatory bid [1][2]. Group 1: Share Reduction Details - The share reduction plan was first disclosed on June 5, 2025 [2]. - The reduction period was from June 26, 2025, to July 9, 2025 [2]. - The shares were sold through centralized bidding (1,996,400 shares) and block trading (3,992,800 shares) [2]. - The price range for the shares sold was between 32.84 and 48.37 yuan per share [2]. - The total amount raised from the share reduction was approximately 220.99 million yuan [2]. Group 2: Shareholder Information - Prior to the reduction, the major shareholder, Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. (科益医药), held 131,778,347 shares, representing 66.01% of the total share capital [3]. - After the reduction, the current holding of the major shareholder is 125,789,147 shares, which is 63.01% of the total share capital [2]. - The shareholding change does not affect the control of the company or its governance structure [2]. Group 3: Company Background - Sinovac Biotech was listed on the Shanghai Stock Exchange's STAR Market on December 14, 2020, with an initial public offering of 49.68 million shares at a price of 22.33 yuan per share [3]. - The total funds raised during the IPO amounted to 1.11 billion yuan, with a net amount of 999.5 million yuan after expenses [3]. - The original fundraising target was 1.70 billion yuan, intended for various projects including drug production facility upgrades and working capital [3].